{
  "id": 14378300,
  "title": "Oruka Therapeutics senior vice president Arjun Agarwal sells $805,888 in stock",
  "url": "https://urgent.news/2026/10/14/oruka-therapeutics-senior-vice-president-arjun-agarwal-sells-805-888",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T05:31:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/oruka-therapeutics-senior-vice-president-arjun-agarwal-sells-805888-in-stock-93CH-4948044"
  },
  "original_language": "en",
  "account": "Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ:ORKA), sold approximately 9,999 shares of the company's stock on October 12, 2026. The transaction, which amounted to $805,888, followed the exercise of employee stock options. Agarwal's sales occurred amidst a remarkable 185% return for ORKA shares over the past year, trading at $78.19. The stock, as per InvestingPro analysis, is currently overvalued relative to its Fair Value estimate. Mr. Agarwal's shares were sold at weighted average prices between $80.0302 and $82.835 per share. These sales were executed pursuant to a Rule 10b5-1 trading plan, established on February 11, 2026. Prior to the sales, Agarwal acquired the same number of shares through employee stock options, which were exercised at prices of $12.50 and $34.39 per share. The stock's recent performance reflects ongoing efforts to strengthen Oruka Therapeutics' management team and its treatment pipeline.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock",
        "url": "https://urgent.news/2026/10/13/mineralys-therapeutics-ceo-jon-congleton-sells-1-9m-mlys-stock",
        "published": "2026-10-13T04:01:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}